The discovery that BRAF (in papillary and anaplastic thyroid cancers) and RET (in MTC) mutations, as well as angiogenesis, play a significant role in tumorigenesis in DTC and MTC led to several clinical trials over the past decade with multikinase inhibitors. The gene discussed is BRAF; the disease is medullary thyroid gland carcinoma.